Published on : 09 Oct 2025, 3:19 pm 2 min read

The Delhi High Court on Thursday upheld a single-judge's order refusing to restrain Hyderabad-based Natco Pharma from producing a drug used in the treatment of Spinal Muscular Atrophy (SMA) [F Hoffman- LA Roche Vs Natco Pharma].

A Division Bench of Justices Hari Shankar and Ajay Digpaul dismissed Swiss drugmaker Roche’s appeal and agreed with the single-judge that Natco had raised a credible challenge to the validity of Roche’s patent for 'Risdiplam', the Active Pharmaceutical Ingredient in its commercial product "EVRYSDI®".

The Court also emphasised that appellate courts should not lightly interfere with discretionary orders refusing interim injunctions.

SMA is a debilitating neuromuscular disorder caused by mutations in the

See Full Page